期刊文献+

肾细胞癌与良性肾肿瘤组织微血管密度和血管内皮细胞生长因子表达的对比研究 被引量:3

Microvascular density and the expression of vascular endothelial growth factor in renal cell carcinoma and benign tumor tissues
下载PDF
导出
摘要 目的:通过检测肾细胞癌、肾脏良性肿瘤标本中的微血管密度(MVD)及血管内皮细胞生长因子(VEGF)表达情况,研究不同性质肾脏肿瘤血管生成的差异。方法:肾细胞癌标本39例,良性肾脏肿瘤标本12例。采用"热点(hotpoint)"法计数MVD,VEGF的定量标准为VEGF染色强度与阳性细胞百分比分值的乘积。结果:MVD、VEGF在肾细胞癌和良性肾脏肿瘤均有表达。肾细胞癌组织MVD(18.3±6.9)计数/视野,VEGF乘积值3.63±2.5(×400),转移者MVD和VEGF乘积值分别为(26.2±7.8)计数/视野、5.83±2.4,未转移者MVD和VEGF乘积值分别为(14.4±4.6)计数/视野、2.06±2.7;12例良性肾脏肿瘤MVD为(2.5±1.3)计数/视野,VEGF乘积值为0.32±0.2。肾细胞癌组织MVD和VEGF表达显著高于良性肾肿瘤(P<0.01),转移组肾细胞癌MVD和VEGF表达显著高于未转移组(P<0.01);肾细胞癌组织MVD与VEGF统计学上呈正相关(r=0.684,P<0.001)。结论:肾细胞癌MVD及VEGF表达均显著高于良性肾脏肿瘤,提示不同性质的肾脏肿瘤其血管生成情况不同,转移肾细胞癌血管生成水平亦高于未转移肾细胞癌,提示血管生成与肾细胞癌转移相关,肾细胞癌组织MVD和VEGF表达水平呈正相关。 Objective To study the difference of the angiogenesis between the renal cell carcinoma (RCC) and benign tumor by detecting the microvascular density (MVD) and the expression of vascular endothelial growth factor (VEGF) in specimens of RCC and benign renal tumors. Methods The specimens of 39 RCC and 12 benign renal tumors were used in the study. The MVD was determined as the mean of microvessel under 5 microscopic vision fields ( × 400). The VEGF expression was detected by immunohistochemical technique. Results The MVD was about (18.3 ± 6.93)/visual field and the quantified VEGF expression was about 3.63 ± 2.5 in RCC tissue ( × 400). And the MVD was about (2.5±1.3) / visual field and the quantified VEGF expression was about 0.32 ± 0.2 in benign tumor tissue. The MVD and quantified VEGF expression were ahout (26.2 ± 7.8) / visual field, 5.83 ± 2.4 and (14.4 ± 4.6) / visual field, 2.06 ± 2.7 in metastatic RCC and non-metastatic tissues, separately. The MVD and VEGF expression in RCC were significantly higher than those in benign renal tumors (P 〈 0.01 ). The MVD and VEGF expressions in metastatic RCC were also significantly higher than those in non-metastatic RCC (P 〈 0.01). The expressions of MVD and VEGF were statistically correlated in 39 RCC (r = 0.684, P 〈 0.001 ). Conclusions The expressions of MVD and VEGF in RCC are significantly higher than those in benign renal tumors, which indicats that anglogenesis in RCC is significantly higher than that in benign renal tumors. The expressions of MVD and VEGF in metastatic RCC are also significantly higher than those in non- metastatic RCC, which reveals that angiogenesis may correlate with metastasis. The MVD has a direct correlation with VEGF expression in tissues of RCC.
出处 《实用医学杂志》 CAS 2008年第18期3132-3134,共3页 The Journal of Practical Medicine
关键词 肾细胞 肾脏肿瘤 微血管密度 血管内皮细胞生长因子 转移 Carcinoma, renal cell Renal neoplasms Microvascular density Vascular endothelial growth factor Metastasis
  • 相关文献

参考文献11

  • 1Folkman J. Angiogenesis research: from laboratory to clinic [J]. Forum (Genova), 1999,9 ( 3 Suppl 3 ) : 59-62.
  • 2Maeda K, Chung Y S, Ogawa Y, et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma [J]. Cancer, 1996,77 (5) : 858-863.
  • 3Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early stage breast carcinoma [J]. J Natl Cancer Inst, 1992,84(24) : 1875-1887.
  • 4李杰,许良中.非P-糖蛋白介导的多药耐药在乳腺癌中的研究[J].肿瘤,2000,20(2):143-145. 被引量:3
  • 5林英城(综述),王鸿彪(综述),曾德(综述).肾细胞癌分子靶向治疗进展[J].国际肿瘤学杂志,2007,34(4):295-298. 被引量:2
  • 6阎洪涛,龚百生,廖勇,杨红,陈照祥.肾细胞癌VEGF表达和MVD检测的临床意义[J].现代泌尿外科杂志,2006,11(6):318-321. 被引量:7
  • 7Stipa F, Lucandri G, Limiti M R, et al. Angiogenesis as a prognostic indicator in renal ductal adenocarcinoma [J]. Anticancer Res, 2002,22 ( 1 A) : 445-449.
  • 8Zhang X, Yamashita M, Uetsuki H, et al. Angiogenesis in renal cell carcinoma: evaluation of microvessel density, vascular endothelial growth factor and matrix metalloproteinases [J]. Int J Urol, 2002,9 (9) :509-514.
  • 9Dekel Y, Koren R, Kugel V, et al. Significance of angiogenesis and microvascular invasion in renal cell carcinoma [J]. Pathol Oncol Res, 2002,8(2) : 129-132.
  • 10Yoshino S, Kato M, Okada K. Prognostic significance of microvessel count in low stage renal cell carcinoma [J]. Int J Urol, 1995,2(3) : 156-160.

二级参考文献32

  • 1张宁,龚侃,果宏峰,那熙,吴关,杨新宇,辛殿旗,那彦群.散发性肾透明细胞癌组织中VHL基因突变、血管内皮生长因子表达及其与微血管形成的关系[J].中华医学杂志,2004,84(19):1620-1624. 被引量:15
  • 2李道兵,罗旭,李春鸣,刘华庆.血管内皮生长因子及受体Flt-1在膀胱癌中的表达及意义[J].贵州医药,2004,28(9):779-782. 被引量:6
  • 3Huang Y,Breast Cancer Res Treat,1997年,42卷,73页
  • 4Schneider E,Cancer Res,1994年,54卷,152页
  • 5Zag Zag D.Angiogenic growth factors in neural embryogensis and neoplasia[J].Am J Pathol,1995,146:293-309.
  • 6Cohen HT, McGovem FJ. Renal-cell carcinoma. N Engl J Med, 2005,353 (23) :2477-2490.
  • 7Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med, 2003,349(5) :427-434.
  • 8Ratain MJ, Flaherty KT, Stadler WM, et al. Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase Ⅱ randomized discontinuation trial (RDT). Proc Am Soc Clin Oncol, 2004,23-381.
  • 9Ratain M J, Eisen T, Stadler WM, et al. Phase Ⅱ placebo- controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol, 2006,24(16) :2505-2512.
  • 10Escudier B, Szczylik C, Eisen T, et al. Randomized phase Ⅲ trial of the Raf kinase and VEGFR inhibitor sorafenib ( BAY 43-9006) in patients with advanced renal cell carcinoma ( RCC ). Proc Am Soc Clin Oncol, 2005,23.380s.

共引文献8

同被引文献30

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部